[1] Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW.Chordomas and cartilaginous tumors at the skull base[J].Cancer, 1973, 32:410-420.
[2] Perzin KH, Pushparaj N. Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx:a clinicopathologic study. ⅩⅣ:chordomas[J]. Cancer, 1986, 57:784-796.
[3] Harbour JW, Lawton MT, Criscuolo GR, Holliday MJ, Mattox DE, Long DM. Clivus chordoma:a report of 12 recent cases and review of the literature[J]. Skull Base Surg, 1991, 1:200-206.
[4] Volpe R, Mazabraud A. A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm)[J].Am J Surg Pathol, 1983, 7:161-170.
[5] Volpe NJ, Liebsch NJ, Munzenrider JE, Lessell S. Neuro -ophthalmologic findings in chordoma and chondrosarcoma of the skull base[J]. Am J Ophthalmol, 1993, 115:97-104.
[6] Leong JL, Batra PS, Citardi MJ. CT-MR image fusion for the management of skull base lesions[J]. Otolaryngol Head Neck Surg, 2006, 134:868-876.
[7] Rassekh CH, Nuss DW, Kapadia SB, Curtin HD, Weissman JL, Janecka IP. Chondrosarcoma of the nasal septum:skull base imaging and clinicopathologic correlation[J]. Otolaryngol Head Neck Surg, 1996, 115:29-37.
[8] Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Mendenhall WM, Suárez C, Rinaldo A, Ferlito A. Clival chordomas:a pathological, surgical, and radiotherapeutic review[J]. Head Neck, 2014, 36:892-906.
[9] Yamaguchi T, Imada H, Iida S, Szuhai K. Notochordal tumors:an update on molecular pathology with therapeutic implications[J]. Surg Pathol Clin, 2017, 10:637-656.
[10] Sakakibara Y, Taguchi Y, Nakamura H, Onodera H, Wakui D, Ikeda T, Aida Y. A case of primary intrasellar chondroid chordoma[J]. No Shinkei Geka, 2019, 47:901-907.
[11] Liu S, Zhou X, Song A, Huo Z, Yao S, Wang Y, Liu Y.Surgical treatment of giant chordoma in the thoracic spine combining thoracoscopic and posterior spinal surgery:a case report[J]. Medicine (Baltimore), 2019, 98:E16990.
[12] Abuzayed B, Alawneh K, Al Qawasmeh M, Raffee L. Clivus intraosseous meningioma mimicking chordoma[J]. J Craniofac Surg, 2019.[Epub ahead of print]
[13] Li L, Wang K, Ma X, Liu Z, Wang S, Du J, Tian K, Zhou X, Wei W, Sun K, Lin Y, Wu Z, Tian J. Radiomic analysis of multiparametric magnetic resonance imaging for differentiating skull base chordoma and chondrosarcoma[J]. Eur J Radiol, 2019, 118:81-87.
[14] Gutierrez A, Rompokos V, Li K, Gillies C, D'Souza D, Solda F, Fersht N, Chang YC, Royle G, Amos RA, Underwood T. The impact of proton LET/RBE modeling and robustness analysis on base-of-skull and pediatric craniopharyngioma proton plans relative to VMAT[J]. Acta Oncol, 2019, 20:1-10.
[15] Chetan MR, Lyon PC, Wu F, Phillips R, Cranston D, Gillies MJ, Bojanic S. Role of diffusion-weighted imaging in monitoring treatment response following high-intensity focused ultrasound ablation of recurrent sacral chordoma[J]. Radiol Case Rep, 2019, 14:1197-1201.
[16] Usher I, Flanagan AM, Choi D. Systematic review of clinical, radiologic, and histologic features of benign notochordal cell tumors:implications for patient management[J]. World Neurosurg, 2019, 130:13-23.